Department of Psychiatry, Vall d'Hebron University Hospital Passeig Vall d´Hebron, 119-129, 08035 Barcelona, EU, Spain.
Curr Neuropharmacol. 2017;15(2):315-323. doi: 10.2174/1570159x14666160324144912.
In the field of dual diagnosis, physicians are frequently presented with pharmacological questions. Questions about the risk of developing psychotic symptoms in cocaine users who need treatment with dopaminergic drugs could lead to an undertreatment.
Review the presence of psychotic symptoms in patients with cocaine abuse/dependence, in treatment with dopaminergic drugs.
Systematic PubMed searches were conducted including December 2014, using the keywords: "cocaine", dopaminergic drug ("disulfuram-methylphenidate-bupropion-bromocriptine-sibutramineapomorphine- caffeine") and ("psychosis-psychotic symptoms-delusional-paranoia"). Articles in English, Spanish, Portuguese, French, and Italian were included. Articles in which there was no history of cocaine abuse/dependence, absence of psychotic symptoms, systematic reviews, and animal studies, were excluded.
313 papers were reviewed. 7 articles fulfilled the inclusion-exclusion criteria. There is a clinical trial including 8 cocaine-dependent patients using disulfiram in which 3 of them presented psychotic symptoms and 6 case-reports: disulfuram (1), methylphenidate (1), disulfiram with methylphenidate (2), and bupropion (2), reporting psychotic symptoms, especially delusions of reference and persecutory ideation.
Few cases have been described, which suggests that the appearance of these symptoms is infrequent. The synergy of dopaminergic effects or the dopaminergic sensitization in chronic consumption are the explanatory theories proposed by the authors. In these cases, a relationship was found between taking these drugs and the appearance of psychotic symptoms. Given the low number of studies found, further research is required. The risk of psychotic symptoms seems to be acceptable if we compare it with the benefits for the patients but a closer monitoring seems to be advisable.
在双相诊断领域,医生经常会遇到药理学方面的问题。例如,需要用多巴胺药物治疗可卡因使用者的精神症状风险问题可能会导致治疗不足。
综述可卡因滥用/依赖患者在接受多巴胺药物治疗时出现精神症状的情况。
系统检索 PubMed 数据库,检索词包括“cocaine”、“dopaminergic drug”(“disulfuram-methylphenidate-bupropion-bromocriptine-sibutramine-apomorphine-caffeine”)和“psychosis-psychotic symptoms-delusional-paranoia”,检索时间截至 2014 年 12 月,纳入英语、西班牙语、葡萄牙语、法语和意大利语文献,排除无可卡因滥用/依赖史、无精神症状、系统评价和动物研究的文献。
共检索到 313 篇文献,7 篇文献符合纳入排除标准。其中包括一项纳入 8 例可卡因依赖患者的临床试验,这些患者使用双硫仑,其中 3 例出现精神症状,6 例为病例报告:双硫仑(1 例)、哌甲酯(1 例)、双硫仑与哌甲酯(2 例)和安非他酮(2 例),均报告出现精神症状,尤其是关系妄想和被害妄想。
目前描述的病例较少,表明这些症状的出现并不常见。作者提出的解释理论是多巴胺效应的协同作用或慢性使用导致的多巴胺敏化。在这些情况下,发现这些药物的使用与精神症状的出现之间存在关联。鉴于研究数量较少,需要进一步研究。与患者的获益相比,出现精神症状的风险似乎可以接受,但需要进行更密切的监测。